Across 160 Phase II/III multiple myeloma trials, the most repeated EU site records cluster around French public hospital networks and Spanish specialist hematology centers. Assistance Publique Hopitaux De Paris leads with 66 site-record appearances, followed by Centre Hospitalier Universitaire De Nantes with 47, Clinica Universidad De Navarra with 45, Hospital Universitario De Salamanca with 41, and Centre Hospitalier Universitaire De Lille with 39.
The top 10 site names account for 362 repeated site-record appearances across the 160-trial analysis frame. The leading five sites contribute 238/362 top-10 appearances, or 65.7%, showing a concentrated operational hub pattern rather than a broad evenly distributed site landscape.
Multiple myeloma site selection appears highly hub-based. AP-HP functions as the largest repeated French network record, while Nantes, Lille, Poitiers, Bordeaux, Tours, and Lyon create a dense French hematology corridor. Spain contributes a second concentrated cluster through Navarra, Salamanca, and Valdecilla.
The dataset includes 94 Phase II trials and 66 Phase III trials. Phase II therefore represents 94/160 trials, or 58.8%, while Phase III represents 66/160 trials, or 41.3%. By authorization year, 2024 contributes 130/160 trials, or 81.3%, compared with 17/160 in 2025 and 13/160 in 2026.
The site pattern is shaped mainly by a large 2024 authorization cohort. Phase II trials outnumber Phase III trials, but the most repeated centers are the same academic hematology hubs that can support both exploratory and confirmatory myeloma programs.
The top-10 site list is concentrated in two countries. France contributes 7/10 sites and 253/362 top-10 site-record appearances, or 69.9%. Spain contributes 3/10 sites and 109/362 appearances, or 30.1%.
The EU myeloma site landscape is not simply “Western Europe-heavy”; it is specifically France-and-Spain-heavy at the top of the site ranking. France contributes breadth through multiple CHU and AP-HP records, while Spain contributes depth through repeatedly selected myeloma specialist hospitals.
Two archetypes explain the top-10 pattern. Public French hospital networks and CHU centers account for 7/10 top sites, while Spanish specialist hematology centers account for 3/10. The top three records alone contribute 158/362 top-10 appearances, or 43.6%.
| Archetype | Top-10 sites | Appearances | Share |
|---|---|---|---|
| French AP-HP / CHU hematology hubs | 7 | 253 | 69.9% |
| Spanish myeloma specialist hospitals | 3 | 109 | 30.1% |
For sponsors planning EU multiple myeloma programs, the data points to two repeatable site-selection strategies: broad French network activation for multi-center coverage, and targeted Spanish myeloma-center activation for disease-specific expertise and investigator continuity.
Site-record appearance means that a site name appeared in a trial geography record. Phase II includes Phase II and Phase I/II records grouped under the Phase II file set. Phase III includes trials grouped under the Phase III file set. AP-HP means Assistance Publique Hopitaux De Paris. CHU means Centre Hospitalier Universitaire.